Appointment of Director of Research & Development

Oxford Pharmascience Group Plc

("Oxford Pharmascience" or the "Company")

Appointment of Director of Research & Development

Oxford Pharmascience, the speciality pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces it has appointed Dr. Liz King as Director of Research & Development to manage all of the Company's development activities. Liz will be responsible for leading and executing the company's development programme focused on the company's two main medicines reformulation programmes in NSAIDs and Statins with reduced side effects. Liz will be a non-board member of the Oxford Pharmascience management team reporting to Marcelo Bravo, Chief Executive Officer.

Dr. Liz King has a comprehensive background in the pharmaceutical industry and in-depth experience of pharmaceutical drug development within the EU and US from the discovery phase through to registration and life-cycle management. Liz has managed multi-functional, international teams, defined and implemented drug development strategies and plans, led due diligence activities, submitted orphan drug applications, managed strategic alliances, participated in FDA and EU regulatory agency meetings and overseen global licence conformance programmes. Liz also has experience of pharmaceutical sciences, technology transfer and business development. Liz has a PhD from the University of Cambridge on polymer science and has worked at Pfizer, Shire Pharmaceuticals, ProStrakan, Mitovie and Pharmalink Consulting.

"I am delighted Dr. Liz King is joining Oxford Pharmascience at this crucial point as we advance a broad pipeline of products into market. Liz is a perfect fit for Oxford PharmaScience with her background in both big Pharma and experience of small, lean organisations. The appointment of Dr. King represents a substantial strengthening of our management team as we continue to move Oxford Pharmascience to a new level of development and performance." 

For further information:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Executive Officer +44 20 7554 5875

N+1 Singer

Aubrey Powell/ Jen Boorer +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.